News

PerkinElmer promotes Prahlad Singh to lead newly created role

PerkinElmer Inc has announced that its board of directors has named Prahlad Singh, President and Chief Operating Officer, effective January 1, 2019. In his expanded position, Dr. Singh will have responsibility for both the Discovery and Analytical Solutions (DAS) and Diagnostics operating divisions of the Company.

This change is being made to better facilitate synergies across the businesses to identify incremental growth opportunities, create operating efficiencies, and most importantly, accelerate the pace of innovation across the Company. Dr. Singh, along with the leaders of the Company’s corporate functions, will continue to report to Robert F. Friel, PerkinElmer’s chairman and chief executive officer.

“It is clear that technologies, applications, and customer needs are converging across DAS and Diagnostics as our customers’ businesses evolve and the lines between therapeutics, diagnostics, food, and digital health are intersecting,” said Friel. “The opportunities for DAS to become an enabler of the sciences of Diagnostics, and vice-versa, continue to grow. Prahlad’s track record of consistently driving strong results operationally, commercially and strategically makes him well qualified to take on this important role. I look forward to working with him as he helps both the Diagnostics and DAS businesses better innovate breakthrough solutions and exceptionally serve our customers, ultimately driving greater value across our markets.”

Dr. Singh joined PerkinElmer in 2014 as president of the Diagnostics business. He was elected an officer of PerkinElmer in 2016 and executive vice president in March 2018. Dr. Singh served as general manager of GE Healthcare’s Women’s Health Business, responsible for the mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and M&A at both GE and Philips Healthcare. From 1995 to 2007, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol Myers Squibb Medical.

Dr. Singh, along with the leaders of the Company’s corporate functions, will continue to report to Robert F. Friel, PerkinElmer’s Chairman and Chief Executive Officer.

Recommended News

Archives